Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of “Moderate Buy” by Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $42.25.

AVTX has been the subject of several recent research reports. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Guggenheim initiated coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Finally, BTIG Research reissued a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, March 24th.

Avalo Therapeutics Price Performance

NASDAQ AVTX opened at $17.76 on Friday. The firm has a market capitalization of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $20.72. The business’s 50-day simple moving average is $15.54 and its 200-day simple moving average is $15.96.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. On average, equities research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Insider Transactions at Avalo Therapeutics

In related news, CFO Christopher Ryan Sullivan sold 7,980 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the transaction, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at approximately $297,346.70. The trade was a 31.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. This represents a 87.56% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 42,130 shares of company stock valued at $693,225. Insiders own 3.03% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BIT Capital GmbH purchased a new position in shares of Avalo Therapeutics in the third quarter valued at $25,000. PFS Partners LLC increased its stake in Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares during the period. Quadrature Capital Ltd acquired a new position in Avalo Therapeutics in the 2nd quarter worth $55,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth $56,000. Finally, Dimensional Fund Advisors LP purchased a new position in Avalo Therapeutics in the 3rd quarter valued at about $143,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.